Transitioning from NAFLD to MAFLD and MASLD: Consistent prevalence and risk factors in a Chinese cohort [0.03%]
从NAFLD过渡到MAFLD和MASLD：中国队列中的流行率和风险因素的一致性分析
Aruhan Yang,Xiaoxue Zhu,Lei Zhang et al.
Aruhan Yang et al.
Julian Varghese
Julian Varghese
Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers [0.03%]
慢病毒载体治疗性疫苗在乙型肝炎小鼠模型及两个乙肝表面抗原携带者中的应用
Yumeng Zhang,Maryline Bourgine,Yanmin Wan et al.
Yumeng Zhang et al.
Background & aims: Immunotherapy for chronic hepatitis B virus (HBV) infection has not yet demonstrated sufficient efficacy. We developed a non-integrative lentiviral-vectored therapeutic vaccine for chronic hepatitis B a...
Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes [0.03%]
从NAFLD到MASLD：新的定义能够更准确地识别出糖尿病高风险个体
Linfeng He,Wenbin Zheng,Kangli Qiu et al.
Linfeng He et al.
The space of Mall confirmed in humans: A response to "Portal venous branches as an anatomic railroad for a gut-bile duct axis" [0.03%]
人类胆管与肠的吻合空间：对“门静脉分支作为解剖铁路”的回应
Iris E M de Jong,Neil D Theise,Rebecca G Wells
Iris E M de Jong
Christy E Trussoni,Nicholas F LaRusso
Christy E Trussoni
Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria? [0.03%]
AFP-L3和DCP在选择肝细胞癌患者进行肝脏移植中的作用：最佳标准是什么？
Meng Sha,Jie Cao,Qiang Xia
Meng Sha
Deleterious variants in TNFAIP3 are associated with type II and seronegative pediatric autoimmune hepatitis [0.03%]
TNFAIP3基因的有害变异与II型和自身抗体阴性的儿童自身免疫性肝炎相关
Sindhu Pandurangi,Astha Malik,Joshua Owens et al.
Sindhu Pandurangi et al.
Reply to: "For long-term outcomes, is the impact of cirrhosis more important than HBsAg seroclearance?" [0.03%]
关于HBsAg转阴与肝硬化对慢乙肝患者长期预后影响的评论
Jimmy Che-To Lai,Grace Lai-Hung Wong,Terry Cheuk-Fung Yip
Jimmy Che-To Lai
Reply to: "Reassessing the causal relationship between liver diseases and cardiovascular outcomes" and "From liver to heart: Enhancing the understanding of cardiovascular outcomes in the UK Biobank" [0.03%]
“ reassessing the causal relationship between liver diseases and cardiovascular outcomes ” 和 “ from liver to heart : Enhancing the understanding of cardiovascular outcomes in the uk biobank ” 的评述
Helena Thomaides-Brears,Rajarshi Banerjee,Amitava Banerjee
Helena Thomaides-Brears